Telaprevir activity in treatment-naive patients infected with hepatitis C virus genotype 4.
Telaprevir activity in treatment-naive patients infected with hepatitis C virus genotype 4.
复制标题
特拉匹韦在感染丙型肝炎病毒基因型 4 的初治患者中的活性。
DOI：
10.1093/infdis/jiu360
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Branch,AndreaD
中科院分区：
文献类型：
--
作者：
Sefcik,RobertaK;Bichoupan,Kian;Martel-Laferrière,Valérie;Odin,JosephA;Liu,LawrenceU;Perumalswami,Ponni;Bansal,Meena;Dieterich,DouglasT;Ahmad,Jawad;Schiano,ThomasD;Branch,AndreaD
TO THE EDITOR—Benhamou et al demonstrated that the tolerability and pharmacokinetics of telaprevir in patients infected with hepatitis C virus (HCV) genotype 4 were similar to those found in HCV genotype 1 patients [1]. In their study, patients infected with HCV genotype 4 were randomly assigned to receive (1) telaprevir monotherapy for 15 days;(2) telaprevir, pegylated interferon alfa-2a, and ribavirin (TPR) for 15 days; or (3) placebo, pegylated interferon alfa-2a, and ribavirin (PR) for 15 days. After the initial 15-day treatment period, study drugs in each group were replaced with standard PR treatment, which was administered for an additional 46–48 weeks.Findings from the study by Benhamou et al supported the investigation of TPR for 12 weeks, followed by PR for an additional 36 weeks, in HCV genotype 4–infected patients. With institutional review board approval, we performed a chart review of HCV genotype 4–infected
